Abdera is building a pipeline of potential best-in-class radiotherapeutics capable of delivering alpha- or beta-emitting radionuclide payloads to a broad range of emerging and clinically …

Abdera is enrolling patients in a Phase 1 clinical of ABD-147 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). For additional information, please visit …

Abdera is leveraging its proprietary ROVEr™ platform to engineer and develop new precision radiotherapeutics with tunable PK properties to maximize therapeutic effect while mitigating …

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage …

Abdera aims to optimize the therapeutic index of potent radioisotopes emitting alpha or beta particles to selectively destroy tumor cells while sparing healthy cells, providing patients with …

2024年6月27日 · Abdera can optimize the delivery and therapeutic index of potent radioisotopes capable of emitting powerful alpha or beta particles to selectively destroy tumor cells while …

Abdera’s differentiated approach to radiopharmaceutical drug discovery and development leverages the capabilities of our R adio O ptimized V ector E nginee r ing (ROVEr™) platform. …

At Abdera Therapeutics, we are seeking curious and committed individuals who are ready for the opportunity to transform the way people living with cancer can be treated. We are relentless in …

2024年5月23日 · Abdera can optimize the delivery and therapeutic index of potent radioisotopes capable of emitting powerful alpha or beta particles to selectively destroy tumor cells while …

2024年8月5日 · Abdera’s Radio Optimized Vector Engineering (ROVEr™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel …